3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Myasthenia Gravis
2
Interventions
rozanolixizumab
8
zilucoplan
7
ravulizumab
6
fludarabine
5
efgartigimod alfa
5
Cyclophosphamide
5
telitacicept
3
Prednisone
3
inebilizumab
2
Rituximab
2
Pyridostigmine Bromide
2
tofacitinib
1
thymoglobulin
1
talquetamab
1
remibrutinib
1
prednylidene
1
iptacopan
1
eculizumab
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
Walk Test
1
Therapeutics
1
Tacrolimus
1
Steroids
1
Robotic Surgical Procedures
1
Psychodrama
1
Prednisolone
1
Plasma Exchange
1
Peripheral Blood Stem Cell Transplantation
1
Oxaloacetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
inebilizumab
×
1 year
×
Clear all
NCT06987539
2026-05-29
THYME
Amgen
Phase 2
Recruiting
15 enrolled
NCT04524273
2026-05-15
MINT
Amgen
Phase 3
Active not recruiting
238 enrolled
36 charts